Tag: 2021新上海419

Government blocks critical news websites, says they have to register

first_img January 13, 2021 Find out more November 8, 2011 – Updated on January 20, 2016 Government blocks critical news websites, says they have to register to go further Reporters Without Borders is appalled to learn that access to four leading news websites –SriLankaMirror, SriLankaGuardian, Paparacigossip9, and LankaWayNews– has been blocked on the media and information ministry’s orders since 6 November, a day after the ministry suddenly announced that news websites with “any content relating to Sri Lanka” needed to register without delay.“We deplore this measure, which reinforces government control over online media,” Reporters Without Borders said. “Several news sites had already been blocked by the government, and now this requirement to register with the information ministry poses an additional serious threat to the already limited online freedom of expression.“We also condemn any attempt to control coverage of the ongoing ‘White Flag’ trial of former army commander Sarath Fonseka or to limit criticism of the government, no matter how virulent, for which journalists have been threatened. The information ministry must lift these blocking orders and rescind this new requirement. And we call on commercial telecom companies to stop blocking sites at the government’s behest.”The announcement that news websites need to register with the media and information ministry and obtain accreditation came on 5 November, shortly after the secretary to the ministry, W.B. Ganegala, had accused certain websites earlier the same day of constantly defaming senior government officials.It is not yet known how news websites are supposed to register or what sanctions they face if they refuse to comply. Some website journalists reportedly went to the ministry and requested registration forms only to discover that no procedures have so far been put in place.The number of blocked sites has risen steadily in recent weeks. They include the Lanka-e-News site, which was blocked at the end of October by state-owned Sri Lanka Telecom (SLT) and privately-owned Internet service provider Dialog Axiata PLC without Lanka-e-News being given any explanation. Reporters Without Borders interviewed Lanka-e-News editor Sandaruwan Senadheera at the time (read the interview). The decision to block the site was upheld by a court today.Sri Lanka is classified as a “country under surveillance” in the Reporters Without Borders report on “Enemies of the Internet” and is ranked 158th out of 178 countries in the Reporters Without Borders annual press freedom index. News Sri LankaAsia – Pacific News July 15, 2020 Find out more Follow the news on Sri Lanka Sri LankaAsia – Pacific Sri Lanka: Journalist manhandled by notorious police inspector currently on trialcenter_img Organisation News Sri Lanka: RSF signs joint statement on attacks against human rights defenders, lawyers and journalists Help by sharing this information Receive email alerts July 29, 2020 Find out more News Sri Lanka: tamil reporter held on absurd terrorism charge RSF_en last_img read more

Start reading Government blocks critical news websites, says they have to register

Sinovac Receives Conditional Marketing Authorization in China for its COVID-19 Vaccine

first_img WhatsApp Sinovac Receives Conditional Marketing Authorization in China for its COVID-19 Vaccine By Digital AIM Web Support – February 8, 2021 Facebook BEIJING–(BUSINESS WIRE)–Feb 8, 2021– Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the China National Medical Products Administration (NMPA) has granted a conditional marketing authorization (CMA) to Sinovac for CoronaVac, Sinovac’s COVID-19 vaccine in individuals aged 18 and above. Sinovac began rolling submission to the NMPA since September 2020 and the NMPA carried out rolling reviews when the submission was made. As of February 4, 2021, the Company made more than 40 submissions to the NMPA. After obtaining the preliminary efficacy results, Sinovac formally filed for application of a conditional marketing authorization on February 3, 2021. The approval is based on the results of the two-month data of phase III clinical trials. The final results are not yet available, and the efficacy and safety results shall be further confirmed. Mr. Yin Weidong, Chairman, President and CEO of Sinovac, said, “Being granted a conditional marketing authorization for CorornaVac is a significant milestone for Sinovac after commencing development at the beginning of 2020. We show our respect and appreciation to the volunteers for their contribution to this research and thank all experts, scientists and partners who participated in this international collaborative project. The COVID-19 pandemic continues around the world, and the fight is far from over. We look forward to providing safe and effective vaccines to as many individuals as possible to combat this epidemic by increasing the vaccination rate. It is our sincere hope that people’s lives and social and economic activities can return to normal as soon as possible, and that we can wear a smile without masks.” CoronaVac is being used under emergency use approval (EUA) in Indonesia, Brazil, Turkey and Chile. Sinovac is also actively seeking regulatory approval of CoronaVac in other countries and regions around the world in an effort to maximize global accessibility and affordability of the COVID-19 vaccine and to ensure global prevention and mitigate spread. About Sinovac Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases. Sinovac’s product portfolio includes vaccines against enterovirus71 (EV71), hepatitis A and B, seasonal influenza, 23-Valent Pneumococcal Polysaccharide (“PPV”), H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), varicella vaccine and mumps. Healive, the hepatitis A vaccine manufactured by the Company, has passed the assessment under WHO prequalification procedures in 2017. The EV71 vaccine, an innovative vaccine developed by Sinovac against hand foot and mouth disease caused by EV71, was commercialized in China in 2016. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, which it has supplied to the Chinese Government’s vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine to the government stockpiling program. The Company is developing a number of new products including COVID-19 vaccine, CoronaVac, a Sabin-strain inactivated polio vaccine and combined vaccines. Sinovac primarily sells its vaccines in China, while also exploring growth opportunities in international markets. The Company is seeking market authorization of its products in over 30 countries outside of China. For more information please see the Company’s website at www.sinovac.com. Safe Harbor Statement This announcement may include certain statements that are not descriptions of historical facts, but are forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar statements. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. In particular, the outcome of any litigation is uncertain, and the Company cannot predict the potential results of the litigation it filed or filed against it by others. Additionally, the triggering of a shareholder rights plan is nearly unprecedented, and the Company cannot predict the impact on the Company or its stock price as a result of the trigger of the rights plan. This announcement contains forward-looking information about the Company’s efforts to develop a potential COVID-19 vaccine that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with clinical data (including the Phase III trial data); the ability to produce comparable clinical or other results, including the rate of vaccine effectiveness and safety and tolerability profile observed to date, in additional analyses of the Phase III trials or in larger, more diverse populations upon commercialization; the risk that clinical trial data are subject to differing interpretations and assessments, and by regulatory authorities; the risk that we may not be able to create or scale up manufacturing capacity on a timely basis or have access to logistics or supply channels commensurate with global demand for any potential approved vaccine, which would negatively impact our ability to supply the estimated numbers of doses of our vaccine candidate; uncertainties regarding the ability to obtain recommendations public health authorities; uncertainties regarding the impact of COVID-19 on our business, operations and financial results; and competitive developments. View source version on businesswire.com:https://www.businesswire.com/news/home/20210208005305/en/ CONTACT: Sinovac Biotech Ltd. Helen Yang Tel: +86-10-8279-9871 or +86-10-5693-1897 Fax: +86-10-6296-6910 Email:[email protected] Inc. Bill Zima U.S.: 1-646-308-1707 Email:[email protected] KEYWORD: INDONESIA MIDDLE EAST UNITED ARAB EMIRATES BRAZIL TURKEY CHINA CHILE SOUTH AMERICA ASIA PACIFIC EUROPE INDUSTRY KEYWORD: INFECTIOUS DISEASES BIOTECHNOLOGY PHARMACEUTICAL HEALTH SOURCE: Sinovac Biotech Ltd. Copyright Business Wire 2021. PUB: 02/08/2021 07:30 AM/DISC: 02/08/2021 07:31 AM http://www.businesswire.com/news/home/20210208005305/en TAGS  Previous articleTumelo Skin Care Introduces So Sensitive! Body LotionNext articleMatterkind Expands Global Reach with Two Strategic Hires Digital AIM Web Support Twittercenter_img Pinterest WhatsApp Local NewsBusiness Pinterest Facebook Twitterlast_img read more

Start reading Sinovac Receives Conditional Marketing Authorization in China for its COVID-19 Vaccine

Contrasting foraging strategies of gannets Morus bassanus at two North Atlantic colonies: foraging trip duration and foraging area fidelity

first_imgSeabirds may be able to increase their foraging efficiency by learning the whereabouts of predictable sources of prey and returning repeatedly to these locations. The occurrence of such foraging area fidelity has been little studied, particularly for pelagic species. We used satellitetelemetry to study foraging behaviour and foraging area fidelity of individual chick-rearing gannets in the North Sea (at the Bass Rock, SE Scotland) and in the Celtic Sea (at Great Saltee, SE Ireland), 2 areas that differ in the distribution of prey. Foraging ranges of adults covered a wide area of ocean up to a maximum range of 540 km at the Bass Rock and 240 km at Great Saltee. At the Bass Rock,individual birds foraged in a single direction or at most in 2 distinct directions, with very similar bearingson successive trips in each direction, significant differences in bearings between individuals and significant repeatability in distances travelled. These results strongly suggest that individuals learned and remembered the locations of feeding sites and used that knowledge on subsequent foraging trips. By contrast at Great Saltee, bearings of successive trips by individuals were much lesssimilar, with highly variable distances to destinations, no differences in bearings among individuals and no significant repeatability in distance travelled. These results indicate a much lower degree of foraging area fidelity at Great Saltee, probably due to a more uniform or less predictable distribution of prey in the Celtic Sea than in the North Sea. Despite marked differences between colonies in distances to trip destinations, durations of foraging trips and foraging area fidelity, the behaviour ofbirds during foraging trips was very similar at the 2 sites: the average speed of travel during foragingtrips was almost identical and birds at both colonies spent about half their time at sea in flight.last_img read more

Start reading Contrasting foraging strategies of gannets Morus bassanus at two North Atlantic colonies: foraging trip duration and foraging area fidelity